Navigation Links
Immunetics Wins $2.8 Million Contract for New Type of HIV Test
Date:5/18/2010

Boston-based Immunetics won a $2.8 million contract from the National Institutes of Health to develop a new test for HIV that will prevent a false positive diagnosis in individuals who have received HIV vaccines in clinical trials. The vaccine response alone results in a false positive result with current HIV tests, resulting in erroneous diagnosis.

Boston, Mass (PRWEB) May 18, 2010 -- Immunetics, Inc. (Boston, MA) has been selected to receive a $2.8 million contract as part of the National Heart, Lung, and Blood Institute’s (NHLBI) Retrovirus Epidemiology Donor Study-II (REDS-II) project, a long term epidemiologic study of blood safety involving HIV and other infectious and non-infectious complications of blood transfusion.

The contract will be administered by Westat, a research organization based in Rockville, MD, which is the coordinating center for the REDS-II project. Under the contract, Immunetics will develop and supply a new test for HIV, which will uniquely distinguish individuals infected with HIV from those who have been immunized with experimental HIV vaccines in clinical trials. At present, vaccination leads to a false positive result on the current generation of HIV screening tests, a problem highlighted by recent publications in medical journals.

Clinical trials for HIV vaccines have involved thousands of vaccine recipients worldwide and continue to enroll more subjects, who stand to benefit from availability of the new test. The NHLBI initiated this project because it will provide a test which will be useful in screening blood donors in those regions of the world where HIV vaccine trials have been or are being conducted and to avoid the permanent deferral of those donors found not to be infected with HIV. Immunetics will work with a consortium of researchers at the National Institutes of Health, the Food and Drug Administration’s Center for Biologics Evaluation and Research where the original research leading to the new test was carried out, Blood Systems Research Institute in San Francisco, and others. The contract is valued at $9.2 million with all options exercised.

“This contract award presents a major opportunity for Immunetics and will leverage our longtime experience in the field of HIV diagnostics and assay development” said Dr. Andrew Levin, Immunetics' CEO and Scientific Director who will be the Principal Investigator on the project. “We see a great fit between our technology and the basic scientific advances made by the research teams at CBER and NIH. Given the vital need for an effective HIV vaccine, the test which we will be developing could play an essential role in current and future vaccine trials. We are particularly pleased to announce this award today, which has been designated by the NIH as National HIV Vaccine Awareness Day, and are very excited by the potential to make a significant contribution to public health in this area.”

Immunetics offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over ten years has been a leading innovator of tests for bacterial, viral and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is better, cost-efficient care through more accurate diagnosis.

Contact: Andrew Levin - 617-896-9100 ext. 13 or alevin(at)immunetics(dot)com

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb4015214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed
2. More Than 1 Million Invitations Anticipated for National ‘Back To Church Sunday,' Set for Sept. 12
3. Millions Are Losing Their Hearing Unnecessarily; Noise-Induced Hearing Loss Is Always Preventable, Says HearUSA Audiologist
4. Infectious diseases caused two-thirds of the nearly 9 million child deaths globally in 2008
5. Enter One Year Auction Contest; You Could Win 5% of Winning Bid or Buy Now - $1 Million Option Proceeds
6. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
7. $1.9 million grant to help UCF find multiple sclerosis nerve-ana
8. NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients
9. MU awarded $8.5 million to explore tiny vessels role in cardiovascular diseases
10. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
11. NIH awards $10 million to Rush University Medical Center to address health disparities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... KOREA (PRWEB) , ... July ... ... receipt of CE marking for its faster PICOPLUS 450 ps pulse width ... picosecond- and nanosecond-domain 1,064-nm neodymium-doped yttrium-aluminum-garnet lasers in tissue-mimicking phantom’ featured in ...
(Date:7/17/2017)... ... July 17, 2017 , ... Summer camp season ... to ensure children are protected from Lyme and other tick-borne diseases. , With ... an increased risk not only for the tick-borne illness, but for its various ...
(Date:7/17/2017)... ... July 17, 2017 , ... HMP , a ... with the Texas Academy of Family Physicians (TAFP) for the 6th ... at the Hyatt Regency Dallas in Dallas, Texas.     , CRS and TAFP will ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
(Date:7/17/2017)... Aliso Viejo, CA (PRWEB) , ... July 17, 2017 , ... ... Pro X. These minimalistic layouts can be used to complement vlogs, professional productions, and ... using the click of a mouse. Manipulate camera controls to make beautiful and unique ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... June 30, 2017  AVACEN Medical (AVACEN) announced the publication of ... describes the use of its AVACEN Treatment Method to ... fibromyalgia. ... AVACEN Medical ... chronic widespread pain. It affects approximately 200 to 400 million people worldwide ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... Netherlands and LAGUNA HILLS, Calif. ... the presentation of new data that validate the use ... risk stratify patients with multiple myeloma (MM). In a ... the European Hematology Association (EHA) in Madrid, ... value of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: